Haematologica
The added value of Bayesian interim analysis in randomized phase II and phase III clinical trials in hemato-oncology.
Anna J T Smit, Niek G Van der Maas, Bronno Van der Holt, Yvette Van Norden, Erik Van Werkhoven, Annette Juul Vangsted, Paula F Ypma, Heleen A Visser-Wisselaar, Rossella Troia, Mario Boccadoro, Bob Löwenberg, Jeroen J W M Janssen, Gert J Ossenkoppele, Fredrik Schjesvold, Pieter Sonneveld
Published: 202510.3324/haematol.2025.288675
Abstract
Not available.